Molecular Biologists study the structure, function, and interactions of biological molecules such as DNA, RNA, and proteins. Their work is essential for understanding cellular processes, genetic regulation, and the mechanisms underlying health and disease. Molecular biology has revolutionized healthcare by providing insights into disease mechanisms, drug discovery, and personalized medicine. Research in this field has led to advancements in treatments for cancer, infectious diseases, and genetic disorders.
In medical research, molecular biologists investigate genetic mutations, gene expression, and molecular pathways that contribute to diseases like cancer, neurodegenerative disorders, and genetic syndromes. Their findings help develop targeted therapies, gene editing techniques, and personalized medicine approaches. In biotechnology and pharmaceutical industries, molecular biologists play a crucial role in drug development, genetic engineering, and the production of biologics, such as vaccines and monoclonal antibodies. They also work on CRISPR and other gene-editing technologies to advance treatments for genetic disorders. Molecular biologists contribute to a wide range of scientific advancements, from improving agricultural crops through genetic modification to developing diagnostic tools for early disease detection. Their research continues to shape innovations in medicine, genetics, and biotechnology, leading to breakthroughs that improve human health and longevity. From regenerative medicine to artificial gene circuits, their discoveries shape the future of healthcare, biotechnology, and environmental sustainability.
Title : Results from a cross-sectional observational study examining irritable bowel syndrome patients six months after finishing their participation in the ViIBS trial
Jacek Piatek, Calisia University, Poland
Title : Gut microbiome as a driver of healthy ageing
Thi Thu Hao Van, RMIT University, Australia
Title : Treating irritable bowel syndrome patients with a balanced multi-strain synbiotic–results from a multi-center, randomized, double-blind, placebo-controlled clinical trial (the ViIBS trial)
Henning Sommermeyer, Calisia University, Poland
Title : Molecular mechanisms underlying the anti-atherogenic actions of probiotics
Dipak P Ramji, Cardiff University, United Kingdom
Title : Global regulatory trends on the use of probiotics and prebiotics in foods and food supplements
David Pineda Ereno, DPE International Consulting, Belgium
Title : Biochemical profile and nutripotential glimpses of Terminalia arjuna bark extract
Suriyavathana Muthukrishnan, Periyar University, India